Open AccessDetermination of gluten immunogenic peptides for the management of the treatment adherence of celiac disease: A systematic review
Author(s) -
Laura Coto,
Irati Mendía,
Carolina Sousa,
Julio C. Bai,
Ángel Cebolla
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i37.6306
Subject(s) - medicine , urine , gluten , gluten free , disease , gastroenterology , feces , serology , immunology , antibody , pathology , biology , microbiology and biotechnology
Gluten is a complex mixture of proteins with immunogenic peptide sequences triggering the autoimmune activity in patients with celiac disease (CeD). Gluten immunogenic peptides (GIP) are resistant to gastrointestinal digestion and are then excreted via the stool and urine. Most common detection methods applied in the follow-up visits for CeD patients such as serology tests, dietetic interviews, questionnaires, and duodenal biopsy have been proved to be inefficient, invasive, or inaccurate for evaluating gluten-free diet (GFD) compliance. Determination of excreted GIP in stool and urine has been developed as a non-invasive, direct, and specific test for GFD monitoring.